To overcome CAF-mediated resistance, a dual-targeting approach was developed: CAR-T cells recognizing both malignant cells via BCMA and CAFs via FAP and SLAMF7 showed enhanced anti-tumor function compared to conventional anti-BCMA CAR-T cells [106]. Here, TNFRSF17 is linked to neoplasm.